ovarian cancer vaccine based on a murine monoclonal antibody and an ovarian cancer pharmaceutical preparation for vaccination consisting of the monoclonal antibody supplied in a proprietary formulation for intravenous, subcutaneous, intraperitoneal or intramuscular injection in humans